Comparison of MDS-003 and MDS-004 trials
| Trial . | Lenalidomide dose (28-day cycle) . | Median age, y (range) . | Isolated 5q deletion . | Median time since diagnosis, y . | Erythroid response* . | Any cytogenetic response . |
|---|---|---|---|---|---|---|
| MDS-003 | 10 mg daily × 21-28 days | 71 (37-95) | 74% | 2.7 | 76% | 73% |
| MDS-004 | 10 mg daily × 21 days or 5 mg daily × 28 days | 69 (36-86) | 76% | 2.5 | 56% | 50% (10 mg arm) 25% (5 mg arm) |
| Trial . | Lenalidomide dose (28-day cycle) . | Median age, y (range) . | Isolated 5q deletion . | Median time since diagnosis, y . | Erythroid response* . | Any cytogenetic response . |
|---|---|---|---|---|---|---|
| MDS-003 | 10 mg daily × 21-28 days | 71 (37-95) | 74% | 2.7 | 76% | 73% |
| MDS-004 | 10 mg daily × 21 days or 5 mg daily × 28 days | 69 (36-86) | 76% | 2.5 | 56% | 50% (10 mg arm) 25% (5 mg arm) |
Erythroid response as defined by 2000 International Working Group Criteria.8